Banook Group becomes European leader in technological services for clinical trials and strengthens its activities and global footprint in central imaging and eCOA (electronic Clinical Outcomes Assessments) Nancy, France, June 11, 2024 – Banook Group,...
Paris, December 19th 2023 Banook Group, the cardiac safety assessment specialist for drug candidates, reinforces its international dimension by welcoming Dr. Mathieu Simon, pharmaceutical and biotechnology industry expert, as independent member to its Supervisory...
Motion Equity Partners announces its entry as the majority shareholder in Banook Group, a leading expert in the Cardiac Safety assessment of drug candidates, alongside Turenne Santé and Banook Group’s management team, who reinvest substantially in the operation....
New Boston office strengthens position in US market, providing local support and greater responsiveness for clinical trials. Press Release by Andrew Llyod and Associates : Nancy (France), and Munich (Germany), September 23, 2021 – TheCompany plans to...
Banook Group acquires German counterpart nabios GmbH to become a European leader in cardiac safety services First external acquisition allows Banook Group to strengthen its presence in Central and Eastern Europe Nancy (France), and Munich (Germany),...
BANOOK GROUP partners with BEPATIENT to offer eCOA/ePRO solutions. In the context of healthcare, an important challenge is how to ensure the continuity of clinical trials. In such trials, which are often very costly, the recruitment, adherence and retention of...
